Prandin (Novo Nordisk)
Welcome to the PulseAid listing for the Prandin drug offered from Novo Nordisk. This Glinide [EPC],Potassium Channel Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novo Nordisk |
| NON-PROPRIETARY NAME: | repaglinide |
| SUBSTANCE NAME: | REPAGLINIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Glinide [EPC],Potassium Channel Antagonists [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2000-01-03 |
| END MARKETING DATE: | 2020-10-31 |
Prandin HUMAN PRESCRIPTION DRUG Details:
| Item Description | Prandin from Novo Nordisk |
| LABELER NAME: | Novo Nordisk |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 0.5(mg/1) |
| START MARKETING DATE: | 2000-01-03 |
| END MARKETING DATE: | 2020-10-31 |
| PRODUCT ID: | 0169-0081_8fad81e2-1d1f-4058-92ee-77f45dd2d7ea |
| PRODUCT NDC: | 0169-0081 |
| APPLICATION NUMBER: | NDA020741 |
Other REPAGLINIDE Pharmaceutical Manufacturers / Labelers:
